Danish pharmaceutical giant Novo Nordisk is gearing up to introduce its blockbuster anti-diabetes and weight-loss drug Wegovy (semaglutide) in India. In a strategic move to gain an advantage over Eli Lilly’s newly launched Mounjaro (tirzepatide), Novo Nordisk has presented data showcasing Wegovy’s cardiovascular benefits in Indian patients, according to recent regulatory filings.
Google Offers Voluntary Exit Packages Amid Strong AI Push
Google has introduced voluntary exit packages for certain employees as part of its ongoing efforts to strengthen its artificial intelligence (AI) initiatives and enhance operational efficiency, according to recent reports. The programme...





Discussion about this post